Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in ...

Retrieved on: 2021-06-04 12:56:15

Tags for this article:

Click the tags to see associated articles and topics

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in .... View article details on hiswai:

Excerpt

No disease progression was reported in the 34 responders (CR + PR), with a 12-month DoR rate of 100%.2. Five percent of patients treated with ...

Article found on: www.prnewswire.com